{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000123","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.012003+00:00","generated_at":"2026-05-28T04:29:53.215768+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bio-Path provides 2025 clinical update; plans IND for obesity drug, advances AML & solid tumor trials","bullets":["Prexigebersen Phase 2 AML trial: biomarker package to identify responders; expects completion of Cohort 2 & interim analysis for Cohort 3 in 2025.","BP1001-A Phase 1/1b solid tumors advanced to second dose cohort; one patient had 15% tumor reduction after 9 cycles; second/third cohorts expected to complete 2025.","BP1002 Phase 1/1b relapsed/refractory AML: third dose cohort (60 mg/m2) enrollment closed faster than expected; no dose limiting toxicities.","New preclinical program: BP1001-A for obesity in Type 2 diabetes; expects to file IND in 2025 after completing preclinical testing.","Patent portfolio includes 7 US patents, 61 foreign patents, and multiple applications pending worldwide."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000123","json":"https://secwatch.observer/filing/0001558370-25-000123.json","markdown":"https://secwatch.observer/filing/0001558370-25-000123.md","text":"https://secwatch.observer/filing/0001558370-25-000123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837025000123/0001558370-25-000123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837025000123/bpth-20250110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:29:53.215768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}